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ABSTRACT
Objectives To evaluate treatment and survival from 
glioblastoma in a real- world setting.
Design and settings A population- based retrospective 
cohort study from Western Norway.
Participants 363 patients aged 18 years or older 
diagnosed with glioblastoma between 1 January 2007 and 
31 December 2014.
Primary and secondary outcome measures Overall 
survival and survival rates determined by Kaplan- Meier 
method, groups compared by log- rank test. Associations 
between clinical characteristics and treatment approach 
assessed by logistic regression. Associations between 
treatment approach and outcome analysed by Cox 
regression.
Results Median overall survival was 10.2 months (95% CI 
9.1 to 11.3). Resection was performed in 221 patients 
(60.9%), and was inversely associated with age over 70 
years, higher comorbidity burden, deep- seated tumour 
localisation and multifocality. Median survival was 13.7 
months (95% CI 12.1 to 15.4) in patients undergoing 
tumour resection, 8.3 months (95% CI 6.6 to 9.9) in 
patients undergoing biopsy and 4.5 months (95% CI 4.0 
to 5.1) in patients where no surgical intervention was 
performed. Chemoradiotherapy according to the Stupp 
protocol was given to 157 patients (43%). Age over 70 
years, higher comorbidity burden and cognitive impairment 
were associated with less intensive chemoradiotherapy. 
Median survival was 16.3 months (95% CI 14.1 to 18.5), 
7.9 months (95% CI 6.7 to 9.0) and 2.0 months (95% CI 0.9 
to 3.2) in patients treated according to the Stupp protocol, 
with less intensive chemoradiotherapy and with best 
supportive care, respectively. Surgical resection (HR 0.61 
(95% CI 0.47 to 0.79)) and chemoradiotherapy according 
to the Stupp protocol (HR 0.09 (95% CI 0.06 to 0.15)) were 
strongly associated with favourable overall survival, when 
adjusted for clinical variables.
Conclusions In a real- world setting, less than half of the 
patients received full- course chemoradiotherapy, with a 
median survival comparable to results from clinical trials. 
Survival was considerably worse in patients receiving less 
intensive treatment. Our results point out a substantial 
risk of undertreating glioblastoma, especially in elderly 
patients.
INTRODUCTION
Glioblastoma WHO grade IV is the most 
frequent of the malignant primary brain 
tumours in adults.1 2 Prognosis is poor, with 
a median overall survival of approximately 11 
months and a 5- year survival of <6% reported 
from population- based materials.1 3 Stan-
dard diagnostic procedures in patients with 
primary brain tumours include neuroimaging 
and histopathological and molecular classifi-
cation.4 However, when clinicians consider a 
biopsy unsafe or not feasible, for example, 
in patients with poor functional status or 
patients harbouring a deep- seated tumour, 
the diagnosis is based solely on radiological 
characteristics. Advanced MRI modalities 
have resulted in a greater ability to differ-
entiate glioblastoma from other intracranial 
lesions.5 6
Gold standard management of glioblas-
toma is maximal safe resection or biopsy 
followed by chemoradiotherapy (CRT).4 7 
Strengths and limitations of this study
 ► This population- based study provides knowledge on 
treatment and survival from glioblastoma in a real- 
world setting, including the establishment of long- 
term survival rates.
 ► To our knowledge, this is the first study to use a 
standardised score in the assessment of comorbidi-
ty burden in patients with glioblastoma.
 ► Detailed information on treatment and complica-
tions were available in all patients, within a common 
patient record system used throughout the region.
 ► We included both patients with histologically con-
firmed glioblastoma and patients with an MRI- based 
diagnosis to counteract the exclusion of elderly, frail 
patients and patients with deep- seated tumours 
where biopsy was considered not feasible.
 ► Limitations of this study included the lack of mo-
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The implementation of the Stupp protocol, that is, radia-
tion therapy given as 60 Gy in 2 Gy fractions with concom-
itant temozolomide (TMZ) followed by six courses of 
TMZ monotherapy, improved overall survival in patients 
with good performance status and age up to 70 years, 
and is currently the gold standard of care.4 8 Several 
targeted therapies have been evaluated in clinical trials, 
however currently not implemented in standard care.9 
Clinical trials have demonstrated that hypofractionated 
radiation therapy with or without TMZ, or TMZ alone 
if O6- methylguanine- DNA methyl transferase (MGMT) 
promoter is methylated, are beneficial treatment options 
in elderly patients.10–12 Best supportive care may be an 
appropriate approach in the elderly and very frail patients, 
particularly in patients with multifocal or large tumours.4 
Elderly patients, patients with poor performance status 
and patients lacking histological confirmation of the 
diagnosis, are excluded from most clinical trials. This may 
result in selection bias and impact survival rates.
We aimed to determine overall survival from glioblas-
toma in an unselected cohort of consecutive patients 
diagnosed with glioblastoma during an 8- year period in a 
geographically defined area of Western Norway. Further-
more, we analysed clinical and radiological characteristics 
associated with treatment approach, and the association 
between treatment intensity and survival.
METHODS
This was a population- based, retrospective cohort study of 
patients diagnosed with glioblastoma between 1 January 
2007 and 31 December 2014. Patients aged 18 years or 
older, diagnosed with International Classification of 
Diseases 10th Revision code C71 (malignant neoplasm 
of brain) or C72 (malignant neoplasm of spinal cord, 
cranial nerves and other parts of central nervous system) 
in the Western region of Norway, were identified through 
electronic medical records. Both patients with histo-
logically verified glioblastoma and patients where the 
glioblastoma diagnosis was based solely on typical MRI 
characteristics were enrolled. Patients from outside the 
region and patients with recurrent glioma, synchronous 
malignancies or lack of informed consent were excluded. 
During the study period, the predefined geographical 
region served a population of approximately 1 020 000.13 
All hospitals provided medical treatment and supportive 
care to patients with glioblastoma. Neurosurgical treat-
ment of patients with brain tumour was centralised to one 
hospital, while radiation therapy was centralised to two 
hospitals in the region.
Demographics and patient characteristics were identi-
fied (table 1). Time of diagnosis was defined as the date 
of the first MRI detecting the primary brain tumour. 
The follow- up period was at least 5 years, or until death. 
We defined patients aged 70 years and older as elderly, 
based on the cut- off value in relevant studies and clin-
ical practice in the region.10 14–17 Comorbidity was classi-
fied according to the Charlson Comorbidity Index.18 We 
registered any cognitive impairment described by clini-
cians, regardless of severity and causation. Radiological 
characteristics were obtained from MRI reports. MGMT 
promoter methylation and IDH (Isocitrate dehydroge-
nase) mutation analyses were not implemented as routine 
analysis in the study period.
Information regarding primary treatment, complica-
tions and survival were collected from medical records. 
Surgery was categorised into resection, biopsy and no 
surgical intervention. Primary CRT was categorised into 
full intensive treatment according to the Stupp protocol, 
less intensive CRT and best supportive care. Treatment 
according to the Stupp protocol was defined as a deliv-
ered radiation dose of 60 Gy (and optional additional 
boost), concomitant TMZ throughout the entire radia-
tion therapy period and at least one out of six planned 
TMZ monotherapy courses fulfilled, in concordance with 
a previous and comparable study.19 Less intensive CRT was 
further classified into (i) full- course radiation therapy (60 
Gy in 2 Gy fractions) and TMZ to a lesser extent than the 
Stupp protocol, (ii) short- course radiation therapy with 
concomitant TMZ and at least one monotherapy TMZ 
course, (iii) short- course radiation therapy with TMZ to 
a lesser extent or no TMZ and (iv) TMZ monotherapy 
without radiation therapy.
Adverse events and complications including infec-
tions, bone marrow suppression grade 3–4 according 
to Common Terminology Criteria for Adverse Events 
(CTCAE) V.5.0, venous thromboembolism, epileptic 
seizures and osteoporosis (defined as low- energy frac-
ture or bone density below −2.5 SD measured by bone 
density scan) were identified. We calculated survival rates 
from time of diagnosis, and defined long- term survival as 
survival of >5 years.
Patient and public involvement
Patients and the public were not involved in this study.
Statistics
We used χ2 test or Fisher’s exact test as appropriate for 
categorical variables. For continuous variables, we used a 
t- test for normally distributed data, otherwise the Mann- 
Whitney U test was used. Verification of normality was 
done by quantile- quantile plots. Clinical and radiolog-
ical characteristics and their associations with treatment 
approach were analysed using binomial logistic regres-
sion. We applied the univariate and multivariate Cox 
proportional hazards regression models to evaluate the 
effect of treatment on overall survival. Cox proportional 
hazard assumption was tested for all variables. Clinical 
and radiological variables considered reasonably likely to 
influence the management approach and outcome were 
included in the models. Survival probabilities were calcu-
lated using a Kaplan- Meier plot and groups compared by 
log- rank test. Two- sided p values <0.05 were considered 
statistically significant. Statistical analyses were performed 
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RESULTS
We identified 381 patients diagnosed with glioblastoma 
in the predefined geographical region between 1 January 
2007 and 31 December 2014. From these, 16 patients were 
excluded according to exclusion criteria (non- resident 
(n=1), previous low- grade or anaplastic glioma (n=10), 
synchronous cancer (n=4) and lack of informed consent 
(n=1)). One patient was lost to follow- up and one patient 
was excluded due to disproved glioblastoma diagnosis by 
autopsy. The remaining 363 patients diagnosed with glio-
blastoma in the predefined period were included. None 
of these participated in clinical trials. Histological confir-
mation of the diagnosis was lacking in 90 patients (24.8%), 
including two patients with non- representative biopsies, in 
whom the diagnosis was based on typical MRI characteris-
tics. Among the 127 patients aged over 70 years, 65 (51.2%) 
lacked histological confirmation of the diagnosis, compared 
with 25 of the 236 patients (10.6%) aged under 70 years.








glioblastoma* n=90 P value
Patient characteristics
  Male gender 211 (58%) 155 (57%) 56 (62%) 0.364
  Age ≥70 years 127 (35%) 62 (23%) 65 (72%) <0.001
Initial symptoms
  Cognitive impairment 171 (47%) 126 (46%) 45 (50%) 0.526
  Headache 159 (44%) 134 (49%) 25 (28%) <0.001
  Monoparesis/Hemiparesis 122 (34%) 85 (31%) 37 (41%) 0.089
  Epilepsy at initial diagnosis 110 (30%) 97 (36%) 13 (14%) <0.001
  Central facial palsy 96 (26%) 65 (24%) 31 (34%) 0.047
  Dysphasia 85 (23%) 63 (23%) 22 (24%) 0.790
  Severe gait dysfunction† 61 (17%) 32 (12%) 29 (32%) <0.001
  Dizziness 62 (17%) 38 (14%) 24 (27%) <0.001
  Visual field loss 54 (15%) 38 (14%) 16 (18%) 0.044
  Previous radiation therapy to brain 4 (1%) 4 (1%) 0 0.486
  Glioblastoma in first- degree relative 3 (1%) 3 (1%) 0 0.318
Tumour characteristics
Tumour localisation
  Frontal 88 (24%) 67 (25%) 21 (23%) 0.897
  Temporal 82 (23%) 68 (25%) 14 (16%) 0.080
  Parietal 28 (8%) 23 (8%) 5 (6%) 0.403
  Occipital 9 (2%) 6 (2%) 3 (3%) 0.526
  Overlapping 108 (30%) 89 (33%) 19 (21%) 0.050
  Deep- seated‡ 46 (13%) 20 (7%) 26 (29%) <0.001
  Corpus callosum invasion 100 (28%) 65 (24%) 35 (39%) 0.005
  Radiological signs of gliomatosis cerebri 8 (2%) 7 (3%) 1 (1%) 0.425
  Multifocality 90 (25%) 68 (25%) 22 (24%) 0.930
MRI contrast enhancement
  Circular (central necrosis) 263 (73%) 194 (71%) 69 (77%) 0.458
  Irregular/Patchy 27 (7%) 21 (8%) 6 (7%) 0.673
  No enhancement 3 (1%) 3 (1%) 0 – 0.546
  Information not available 45 (12%) 35 (13%) 10 (11%) 0.670
Results presented in absolute numbers and % of total. Comparison between groups (histologically confirmed glioblastoma and MRI- based 
glioblastoma diagnosis) was performed by χ2 test (Fisher’s exact test when expected cell count <5).
Significant p values are in bold.
*Highly suspected glioblastoma based on typical MRI characteristics, biopsy not performed.
†Inability to walk without support.
‡Thalamus, basal ganglia, internal capsule, splenium corpus callosum, mesencephalon, brain stem and cerebellum.
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Tumour and patient characteristics
Median age at the time of diagnosis was 64.6 years (range 
18.1–94.9). Median age in patients with histologically 
confirmed glioblastoma was 61.5 years (range 18.1–86.1), 
compared with 77.0 years (range 35.0–94.9) in patients 
with an MRI- based diagnosis (p<0.0001). Mean Charlson 
Comorbidity Index was 3.9 (SD 1.4) in patients with histo-
logically confirmed glioblastoma, compared with 5.7 (SD 
1.6) in patients with an MRI- based diagnosis (p<0.0001). 
Male/female ratio was 1.39. Additional patient and 
tumour characteristics are outlined in table 1.
Headache and epilepsy were more frequent in patients 
with histologically confirmed glioblastoma compared with 
patients with an MRI- based diagnosis, while dizziness and 
gait dysfunction were more frequent among patients with 
an MRI- based diagnosis. Classification of performance 
status by validated screening tools (eg, Eastern Coopera-
tive Oncology Group and Karnofsky score) was not appli-
cable due to insufficient documentation of performance 
status in the medical records.
Treatment and complications
Surgical resection was performed in 221 of 363 patients 
(60.9%). Radiation therapy was given to 323 patients 
(89.0%), where full- course radiation therapy (60 Gy or 
60 Gy with additional boost) was planned or commenced 
in 218 patients. Among these 218 patients, 14 (6.4%) 
had the treatment cancelled (n=1), discontinued (n=5) 
or converted to a short- course regimen (n=8). Change in 
radiation therapy plan was due to poor general condition 
or rapid clinical deterioration (n=11), patient preferences 
(n=2) or acute complications (n=1). Furthermore, 120 
patients were allocated to short- course radiation therapy. 
Among these, the treatment was cancelled (n=13) or 
discontinued (n=11) in 24 patients (20.0%), due to poor 
general condition (n=14), acute complications (n=7) or 
patient preferences (n=3).
CRT according to the Stupp protocol was prepared or 
commenced in 185 patients, while the treatment plan 
was changed or prematurely interrupted in 28 of these 
(15.1%). Consequently, 157 patients (43.3% of the total 
cohort) received CRT according to the Stupp protocol, 
including 11 patients without histological confirmation. 
Nine of these 11 patients had deep- seated tumours. In 
patients receiving adjuvant TMZ, regardless of radiation 
therapy dose, the mean number of TMZ courses was 4.6 
(range 1–14). Nine of the patients who underwent resec-
tion were not eligible for CRT, due to complications, 
rapid progression or poor general condition. Among 236 
patients aged under 70 years, 144 (61.0%) received CRT 
according to the Stupp protocol, 85 patients (36.0%) 
received less intensive CRT and 7 patients (3.0%) received 
best supportive care. In the cohort of 127 patients aged 
over 70 years, 13 (10.2%) received CRT according to the 
Stupp protocol, 82 patients (64.6%) received less inten-
sive CRT and 32 patients (25.2%) received best supportive 
care.
Associations between patient and tumour charac-
teristics and treatment approach are presented in 
table 2. Elderly patients, patients with multifocal or 
deep- seated tumours and patients with higher comor-
bidity burden were less likely to undergo surgical 
resection, according to adjusted logistic regression 
analyses. Elderly patients, patients with cognitive 
impairment, patients with increasing comorbidity 
burden and females were less likely to receive CRT 
according to the Stupp protocol.
In total, 188 patients (51.8%) had at least one 
epileptic seizure, the majority at the time of diagnosis. 
Table 2 Associations between patient and tumour characteristics and treatment approach in 363 patients diagnosed with 
glioblastoma between January 2007 and December 2014
No resection CRT less intensive than Stupp protocol†
Unadjusted Adjusted Unadjusted Adjusted
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Female gender 1.1 (0.7 to 1.6) 1.0 (0.6 to 1.7) 1.7 (1.1 to 2.5)* 1.8 (1.1 to 3.1)*
Age ≥70 years 4.5 (2.9 to 7.2)*** 3.0 (1.5 to 6.3)** 13.7 (7.3 to 25.8)*** 5.1 (2.2 to 11.8)***
Cognitive impairment 1.2 (0.8 to 1.8) 1.2 (0.8 to 2.1) 1.8 (0.6 to 1.7)** 1.8 (1.1 to 3.0)*
Charlson Comorbidity 
Index
1.5 (1.3 to 1.8)*** 1.3 (1.0 to 1.6)* 2.2 (1.8 to 2.6)*** 1.6 (1.2 to 2.0)***
Multifocal tumour 1.9 (1.2 to 3.1)** 2.6 (1.5 to 4.6)* 1.2 (0.7 to 1.9) 1.6 (0.9 to 2.9)
Deep- seated tumour‡ 7.3 (3.5 to 15.3)*** 10.0 (4.4 to 22.3)*** 1.4 (0.7 to 2.6) 1.5 (0.7 to 3.2)
Significant p values are in bold.
*Two- sided p values <0.05 were considered statistically significant; *p<0.05; **p<0.01; ***p<0.001; results not marked by an asterisk are not 
significant.
†Stupp protocol=radiation therapy 60 Gy in 2 Gy fractions (delivered), fulfilled concomitant TMZ and fulfilled at least one out of six planned 
TMZ monotherapy courses.
‡Thalamus, basal ganglia, internal capsule, splenium corpus callosum, mesencephalon, brain stem and cerebellum.
CRT, chemoradiotherapy; TMZ, temozolomide.
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Venous thromboembolism (deep venous thrombosis 
of extremity, pulmonary embolism or sinus vein 
thrombosis) occurred in 75 patients (20.7%), while 
26 patients (7.2%) were diagnosed with osteoporosis. 
Among 247 patients receiving initial chemotherapy, 
CTCAE grade 3–4 bone marrow suppression, that is, 
platelet count <50.0×109/L and/or neutrophil count 
<1.0×109/L, occurred in 37 patients (15.0%). Fifty- 
eight patients (23.5%) had bacterial or viral infections, 
while 11 patients (4.5%) experienced septicaemia or 
neutropenic fever.
Survival
Median overall survival was 10.2 months (95% CI 
9.1 to 11.3 months). One- year, 2- year, 3- year and 
5- year survival rates were 41.3%, 17.3%, 9.1% and 
4.1%, respectively. Median survival among patients 
with histologically confirmed glioblastoma was 12.6 
months (95% CI 11.4 to 13.8), compared with 4.5 
months (95% CI 4.0 to 5.1) in patients with an MRI- 
based diagnosis (p<0.0001). In total, 354 of the 363 
included patients (97.5%) died during the study 
period, and one patient was lost to follow- up. Kaplan- 
Meier curves of survival according to age, surgery and 
CRT are presented in figure 1. Median survival in 
patients aged under 70 years was 13.5 months (95% CI 
12.1 to 14.9), compared with 5.2 months (95% CI 4.1 
to 6.3) in patients aged over 70 years. Median survival 
in patients who underwent resection was 13.7 months 
(95% CI 12.1 to 15.4), compared with 8.3 months 
(95% CI 6.6 to 9.9) for those who underwent biopsy, 
and 4.5 months (95% CI 4.0 to 5.1) in patients with 
no surgical intervention. Median survival in patients 
receiving CRT according to the Stupp protocol was 
16.3 months (95% CI 14.1 to 18.5), compared with 7.9 
months (95% CI 6.7 to 9.0) and 2.0 months (95% CI 
0.9 to 3.2) in patients treated with less intensive CRT 
or best supportive care, respectively. In patients aged 
over 70 years and receiving CRT according to the Stupp 
protocol, median survival was 21.4 months (95% CI 
7.5 to 35.3), compared with 6.0 months (95% CI 4.7 
to 7.7) and 2.0 months (95% CI 0.7.3.4) in those 
treated with less intensive CRT or best supportive 
care. Among 157 patients receiving CRT according to 
the Stupp protocol, 49 patients (31.2%) survived for 
>2 years, and 14 patients (8.9%) survived for >5 years.
Univariate and multivariate Cox proportional 
hazards regression models of overall survival are 
presented in table 3. Resection compared with no 
Figure 1 Overall survival in 363 adults diagnosed with glioblastoma between January 2007 and December 2014. (A) Survival 
by age. (B) Survival by surgical treatment. (C) Survival by chemoradiotherapy. (D) Survival by chemoradiotherapy in patients 
aged 70 years or older. Stupp protocol is here defined as completed radiation therapy in total dose of 60 Gy in 2 Gy fractions, 
concomitant temozolomide in the entire radiation therapy period and completed at least one out of six planned temozolomide 
monotherapy courses. Cumulative survival in months with 95% CI bands. Groups compared with log- rank test.
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resection was strongly associated with improved 
overall survival according to multivariate analyses 
(HR 0.61, p<0.001). CRT according to the Stupp 
protocol (HR 0.09, p<0.001) and less intensive CRT 
(HR 0.17, p<0.001) were strongly associated with 
better outcomes.
An alluvial diagram visualises the consecutive treat-
ment modalities and the association with median 
Table 3 Univariate and multivariate Cox regression analysis of overall survival in 363 patients diagnosed with glioblastoma 
between January 2007 and December 2014
Variables
Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Female gender 1.04 (0.784 to 1.29) 0.71 0.91 (0.73 to 1.14) 0.40
Age ≥70 years 3.00 (2.38 to 3.77) <0.001 1.32 (0.93 to 1.87) 0.12
Cognitive impairment 1.25 (1.01 to 1.54) 0.04 1.06 (0.84 to 1.32) 0.64
Charlson Comorbidity Index 1.44 (1.34 to 1.54) <0.001 1.22 (1.10 to 1.35) <0.001
Deep- seated tumour* 1.78 (1.30 to 2.44) <0.001 1.54 (1.09 to 2.19) 0.02
Multifocality 1.53 (1.20 to 1.95) <0.01 1.42 (1.09 to 1.84) <0.01
Surgical treatment
  No resection Ref Ref
  Resection 0.39 (0.31 to 0.48) <0.001 0.61 (0.47 to 0.79) <0.001
Chemoradiotherapy (CRT)
  No CRT Ref Ref
  Less intensive CRT 0.12 (0.08 to 0.18) <0.001 0.17 (0.11 to 0.26) <0.001
  Stupp protocol† 0.05 (0.03 to 0.07) <0.001 0.09 (0.06 to 0.15) <0.001
HR, 95% CI and p values calculated by univariate and multivariate Cox proportional hazards regression model. P values <0.05 were 
considered statistically significant.
Significant p values are in bold.
*Thalamus, basal ganglia, internal capsule, splenium corpus callosum, mesencephalon, brain stem and cerebellar vermis.
†Radiation therapy 60 Gy in 2 Gy fractions (delivered), fulfilled concomitant TMZ and fulfilled at least one out of six planned TMZ 
monotherapy courses.
TMZ, temozolomide.
Figure 2 Alluvial diagram visualising associations between combination of treatment modalities and median survival in an 
unselected cohort of 363 patients diagnosed with glioblastoma between January 2007 and December 2014. The width of the 
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survival (figure 2). In the whole cohort, 15 patients 
(4.1%) achieved long- term survival of >5 years. Twelve 
of these patients underwent surgical resection, 
whereas three had a biopsy alone. Moreover, 14 out of 
15 long- term surviving patients completed the Stupp 
protocol, while one patient received hypofractionated 
radiation therapy followed by TMZ monotherapy. All 
15 long- term surviving patients completed at least six 
maintenance TMZ courses (range six to nine).
DISCUSSION
Median overall survival in our cohort of 363 consecutive 
patients diagnosed with glioblastoma was approximately 
10 months. Surgical resection and full- course CRT were 
strongly associated with improved survival, as demon-
strated by multivariate Cox regression. However, only two- 
thirds of the patients underwent resection, and less than 
half of the patients received CRT according to the Stupp 
protocol. Age over 70 years was strongly associated with 
less intensive treatment, both surgery and CRT. Irrespec-
tive of age, those who received treatment according to the 
Stupp protocol, had a favourable prognosis with median 
survival and long- term survival rates comparable to those 
observed in clinical trials. Survival was considerably worse 
in elderly patients and patients receiving less intensive 
treatment. A significant number of patients received best 
supportive care only, thus the overall survival was poorer 
in this population- based study compared with results 
from clinical trials.
Histological confirmation of the diagnosis was lacking 
in approximately 25% of the patients in our cohort. There 
are limited real- world data describing the frequency of 
omitting biopsy in patients with a high suspicion of glio-
blastoma according to MRI. A previous Norwegian study 
reported that 12% of the patients diagnosed with glioblas-
toma had a diagnosis based solely on radiological pattern 
or autopsy.20 Conversely, an English population- based 
study reported that <10% of patients aged under 70 years, 
and 40% of patients aged over 70 years, lacked histolog-
ical confirmation of the diagnosis, comparable to our 
findings.21 We found that patients with MRI- based diag-
noses were older and had a higher comorbidity burden, 
and they more often had deep- seated tumours. In addi-
tion, they more commonly presented with dizziness 
and gait disturbances, which are vague and often slowly 
progressing symptoms that may have led to a delay in diag-
nosis compared with patients presenting with epileptic 
seizure or headache. It is reasonable to assume that 
established experiences and traditions among clinicians 
may influence the choice of intervention, for example, 
emphasising the risk of complications related to neuro-
surgery in elderly or frail patients, and patients with deep- 
seated tumours. The dismal prognosis of patients not 
undergoing resection is another possible contributing 
factor to the choice of this managment. A further reason 
may be the improvement of MRI techniques, including 
perfusion- weighted imaging and diffusion- weighted MRI, 
facilitating the distinction of glioblastoma from other 
intracranial lesions.22 23 However, in order to increase the 
diagnostic accuracy, biopsy should also be recommended 
in patients considered unlikely to benefit from resection, 
when considered feasible and safe.
Resection was performed in 61% of the patients in 
this cohort, in line with the aforementioned study from 
England.21 However, the resection rate was lower than 
reported in other previous population- based studies, 
where 74% of patients underwent resection.3 19 A possible 
explanation is our inclusion of patients with an MRI- based 
glioblastoma diagnosis, and a higher number of patients 
with deep- seated tumours. Patients who underwent resec-
tion had a significantly better survival than those who 
underwent biopsy or no surgical intervention.
Nearly 90% of the patients in our cohort received 
radiotherapy, the majority in combination with TMZ. 
Multivariate Cox regression, with adjustment for age and 
other clinical variables, demonstrated improved overall 
survival in patients receiving CRT according to the Stupp. 
However, less than half of the patients received CRT 
according to the Stupp protocol, similar to the findings 
of Lwin et al.19 We assume that the frequency of elderly 
patients, patients with a significant comorbidity burden 
and patients with extensive symptoms including cognitive 
impairment, influence the choice of therapeutic inten-
sity and the capacity of patients to complete commenced 
treatment. Patients aged over 70 years received less 
intensive treatment compared with younger patients, in 
concordance with previous studies of elderly patients with 
glioblastoma.3 14 15 21
Median overall survival in our cohort was approxi-
mately 10 months, comparable with results from previous 
population- based studies with median survival ranging 
from 6.1 to 15.3 months.3 19–21 24 25 A 5- year survival rate 
of approximately 4% was equal to that reported in large 
population- based materials.1 21 A recent systematic review 
reported a superior median overall survival of 15.6 
months in the post- Stupp era.26 However, nearly one- 
third of the studies included in this review article were 
clinical trials, with an expected superiority in survival 
rates compared with population- based materials. In our 
cohort, outcome was considerably better in patients 
receiving CRT according to the Stupp protocol, with a 
median survival of approximately 16 months and a 5- year 
survival rate of 8.9%. This was in line with the results 
from the randomised clinical trial by Stupp et al, where 
median survival in the CRT arm was 14.6 months, and 
5- year survival was 9.8%.8 27 Our results highlight the gap 
between the survival rates reported from clinical studies 
and those observed in a real- world setting.
Median overall survival in patients aged over 70 years 
was 5.2 months in our cohort, in line with previous 
population- based studies where median survival ranged 
from <3–4 months.14 15 17 21 Survival in elderly patients in 
our cohort was strongly associated with a CRT treatment 
approach, and ranged from 2 months in patients receiving 
best supportive care to 21 months in patients receiving 
copyright.
 on A











pen: first published as 10.1136/bm





8 Bjorland LS, et al. BMJ Open 2021;11:e043208. doi:10.1136/bmjopen-2020-043208
Open access 
CRT according to the Stupp protocol. This was compa-
rable to results from previous population- based studies in 
elderly patients.3 28 As expected, median overall survival 
in elderly patients was lower in our unselected cohort 
than that demonstrated in prospective clinical trials, 
where median survival ranged from 5.2 to 9.6 months 
depending on CRT.10–12 16 A recent Cochrane analysis 
concluded that CRT improved survival compared with 
radiation therapy alone in elderly patients capable of self- 
care.29 The improved survival in elderly patients receiving 
combined CRT, both in our cohort and previous studies, 
demonstrates a potential benefit from intensive treatment 
in this group.3 11 28 30 A disregard of this issue may risk 
potentially undertreating elderly patients. Nevertheless, 
in patients of advanced age, or suffering from extensive 
disabilities, best supportive care may be an appropriate 
approach.
As concerns the methodology of our study, we regard 
the population- based design as a strength. The long- term 
follow- up of an unselected cohort provides knowledge on 
treatment and survival from glioblastoma, including the 
establishment of long- term survival rates, and the inclu-
sion period ensured that all included patients were diag-
nosed with glioblastoma after the implementation of the 
current standard treatment. Other strengths were the low 
dropout rate of only one patient (0.3%), and the detailed 
clinical information on treatment and complications 
available in all patients within a common patient record 
system throughout the region. Among the limitations 
of the study was the lack of molecular analyses. Further-
more, performance status was not sufficiently described 
in medical records and not applicable to validated 
screening tools. To counteract this, comorbidity burden, 
cognitive impairment and gait dysfunction were included 
in the analyses. In addition, surgical resection was not clas-
sified into degree of resection; hence, the survival curves 
did not differentiate between macroscopic complete and 
partial resection. The inclusion of patients with MRI- 
based diagnosis can be considered both a disadvantage 
and an advantage. To reduce the risk of incorrect inclu-
sion of patients without glioblastoma, we included only 
patients when clinicians and radiologists unequivocally 
considered glioblastoma the most likely diagnosis. Even 
though biopsy is highly recommended and is standard of 
care, it is not always considered feasible and safe. There-
fore, the inclusion of these patients provides knowledge 
on the diagnostic approach and survival of all patients 
with highly suspected glioblastoma based on MRI.
In conclusion, the prognosis of glioblastoma was 
considerably worse in a real- world setting compared with 
results from clinical trials. In patients receiving treat-
ment according to the Stupp protocol, survival rates were 
comparable to that achieved in clinical trials. Multivar-
iate Cox regression demonstrated that both resection 
and CRT were strongly associated with better outcome. 
However, only two- thirds of the patients in our cohort 
underwent resection, and less than half of the patients 
received treatment according to the Stupp protocol. Our 
results point towards a substantial risk of undertreating 
patients with glioblastoma, especially in elderly patients, 
and a potential benefit from choosing a more aggressive 
treatment approach.
Author affiliations
1Department of Clinical Medicine, University of Bergen Faculty of Medicine and 
Dentistry, Bergen, Norway
2Department of Haematology and Oncology, Stavanger University Hospital, 
Stavanger, Norway
3Department of Oncology and Medical Physics, Haukeland Universitetssjukehus, 
Bergen, Norway
4Department of Clinical Science, University of Bergen Faculty of Medicine and 
Dentistry, Bergen, Norway
5Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway
6Department of Neurology, Stavanger University Hospital, Stavanger, Norway
Acknowledgements The authors would like to thank Anastasia Ushakova at 
Stavanger University Hospital for support in statistical analyses, and Joanna Haynes 
at Stavanger University Hospital for proofreading the article.
Contributors All coauthors have contributed to the design of the work and, 
are accountable for all its aspects. LSB, OF and EF initiated the study and were 
responsible for study design and data collecting. LSB was responsible for statistical 
analyses, contributed by OF, BG, RM and EF, with support from statistician AU. All 
coauthors participated in the interpretation of the results. LSB and OF designed the 
figures. LSB drafted the initial manuscript, and all coauthors reviewed and edited 
the paper. All coauthors approved the final version of the manuscript.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not- for- profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval The study was approved by the Regional Committee for Medical 
and Health Research Ethics (no. 2014/1931). Informed consent was obtained 
from patients alive at the time of inclusion. A waiver of consent was approved for 
deceased patients.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement No data are available.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iD
Line Sagerup Bjorland http:// orcid. org/ 0000- 0003- 3043- 7804
REFERENCES
 1 Ostrom QT, Gittleman H, Truitt G, et al. CBTRUS statistical report: 
primary brain and other central nervous system tumors diagnosed in 
the United States in 2011-2015. Neuro Oncol 2018;20:iv1–86.
 2 Wen PY, Huse JT. 2016 World Health organization classification of 
central nervous system tumors. Continuum 2017;23:1531–47.
 3 Hansen S, Rasmussen BK, Laursen RJ, et al. Treatment and survival 
of glioblastoma patients in Denmark: the Danish neuro- oncology 
registry 2009-2014. J Neurooncol 2018;139:479–89.
 4 Weller M, van den Bent M, Hopkins K, et al. EANO guideline for the 
diagnosis and treatment of anaplastic gliomas and glioblastoma. 
Lancet Oncol 2014;15:e395–403.
 5 Saini J, Kumar Gupta P, Awasthi A, et al. Multiparametric imaging- 
based differentiation of lymphoma and glioblastoma: using T1- 
perfusion, diffusion, and susceptibility- weighted MRI. Clin Radiol 
2018;73:986.e7–986.e15.
 6 Suh CH, Kim HS, Jung SC, et al. Perfusion MRI as a diagnostic 
biomarker for differentiating glioma from brain metastasis: a 
systematic review and meta- analysis. Eur Radiol 2018;28:3819–31.
copyright.
 on A











pen: first published as 10.1136/bm





9Bjorland LS, et al. BMJ Open 2021;11:e043208. doi:10.1136/bmjopen-2020-043208
Open access
 7 Sulman EP, Ismaila N, Armstrong TS, et al. Radiation therapy for 
glioblastoma: American Society of clinical oncology clinical practice 
guideline endorsement of the American Society for radiation 
oncology guideline. J Clin Oncol 2017;35:361–9.
 8 Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus 
concomitant and adjuvant temozolomide for glioblastoma. N Engl J 
Med Overseas Ed 2005;352:987–96.
 9 Mohtashami E, Shafaei- Bajestani N, Mollazadeh H, et al. The current 
state of potential therapeutic modalities for glioblastoma multiforme: 
a clinical review. Curr Drug Metab 2020;21:564–78.
 10 Malmström A, Grønberg BH, Marosi C, et al. Temozolomide versus 
standard 6- week radiotherapy versus hypofractionated radiotherapy 
in patients older than 60 years with glioblastoma: the Nordic 
randomised, phase 3 trial. Lancet Oncol 2012;13:916–26.
 11 Perry JR, Laperriere N, O'Callaghan CJ, et al. Short- Course radiation 
plus temozolomide in elderly patients with glioblastoma. N Engl J 
Med 2017;376:1027–37.
 12 Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy 
alone versus radiotherapy alone for malignant astrocytoma in 
the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 
2012;13:707–15.
 13 Statistics Norway. 2020:Population and area (M):2007–20.
 14 Coate L, McNamara MG, Lwin Z, et al. Glioblastoma treatment 
in the elderly in the temozolomide therapy era. Can J Neurol Sci 
2014;41:357–62.
 15 Gately L, Collins A, Murphy M, et al. Age alone is not a predictor for 
survival in glioblastoma. J Neurooncol 2016;129:479–85.
 16 Minniti G, De Sanctis V, Muni R, et al. Hypofractionated radiotherapy 
followed by adjuvant chemotherapy with temozolomide in elderly 
patients with glioblastoma. J Neurooncol 2009;91:95–100.
 17 Pretanvil J- A, Salinas IQ, Piccioni DE. Glioblastoma in the elderly: 
treatment patterns and survival. CNS Oncol 2017;6:19–28.
 18 Charlson M, Szatrowski TP, Peterson J, et al. Validation of a 
combined comorbidity index. J Clin Epidemiol 1994;47:1245–51.
 19 Lwin Z, MacFadden D, Al- Zahrani A, et al. Glioblastoma management 
in the temozolomide era: have we improved outcome? J Neurooncol 
2013;115:303–10.
 20 Rønning PA, Helseth E, Meling TR, et al. A population- based study 
on the effect of temozolomide in the treatment of glioblastoma 
multiforme. Neuro Oncol 2012;14:1178–84.
 21 Brodbelt A, Greenberg D, Winters T, et al. Glioblastoma in England: 
2007-2011. Eur J Cancer 2015;51:533–42.
 22 Chiang IC, Kuo Y- T, Lu C- Y, et al. Distinction between high- grade 
gliomas and solitary metastases using peritumoral 3- T magnetic 
resonance spectroscopy, diffusion, and perfusion imagings. 
Neuroradiology 2004;46:619–27.
 23 Radbruch A, Wiestler B, Kramp L, et al. Differentiation of 
glioblastoma and primary CNS lymphomas using susceptibility 
weighted imaging. Eur J Radiol 2013;82:552–6.
 24 Teo M, Martin S, Owusu- Agyemang K, et al. A survival analysis of 
GBM patients in the West of Scotland pre- and post- introduction of 
the Stupp regime. Br J Neurosurg 2014;28:351–5.
 25 Bruhn H, Strandéus M, Milos P. Improved survival of Swedish 
glioblastoma patients treated according to Stupp 2018;138:332–7.
 26 Marenco- Hillembrand L, Wijesekera O, Suarez- Meade P, 
et al. Trends in glioblastoma: outcomes over time and type of 
intervention: a systematic evidence based analysis. J Neurooncol 
2020;147:297–307.
 27 Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with 
concomitant and adjuvant temozolomide versus radiotherapy 
alone on survival in glioblastoma in a randomised phase III 
study: 5- year analysis of the EORTC- NCIC trial. Lancet Oncol 
2009;10:459–66.
 28 Rusthoven CG, Koshy M, Sher DJ, et al. Combined- Modality 
therapy with radiation and chemotherapy for elderly patients with 
glioblastoma in the temozolomide era: a national cancer database 
analysis. JAMA Neurol 2016;73:821–8.
 29 Hanna C, Lawrie TA, Rogozińska E, et al. Treatment of newly 
diagnosed glioblastoma in the elderly: a network meta- analysis. 
Cochrane Database Syst Rev 2020;3:Cd013261.
 30 Youssef M, Ludmir EB, Mandel JJ, et al. Treatment strategies for 















pen: first published as 10.1136/bm
jopen-2020-043208 on 12 M
arch 2021. D
ow
nloaded from
 
